Abstract
Objective
This work investigated the profile of inflammation biomarkers in patients with chronic hepatitis C and its association with liver fibrosis, hepatic necroinflammatory activity, viral genotypes and cryoglobulinemia.
Subjects and methods
Seventy-eight untreated patients were studied. Biomarker levels were determined by immunoassays, cryoglobulinemia by cryoprecipitation and liver histopathology investigated using METAVIR scores.
Results
Decreased levels of α1-acid glycoprotein (AGP), C3 and haptoglobin (Hp) were observed in the patients (P < 0.0001). Increased α1-antitrypsin (P < 0.01) and ferritin (P < 0.0001) levels were found in this group, but C-reactive protein (CRP) and C4 levels were unaltered. Alanine aminotransferase inversely correlated with Hp (P < 0.01) and AGP (P = 0.01), whereas it was directly correlated with ferritin (P < 0.05) and AGP (P < 0.0001). The levels of CRP, C3 and C4 were lower in the patients with hepatic necroinflammatory activity (P < 0.05). Patients with advanced fibrosis had low levels of Hp and AGP (P < 0.05 and P < 0.01, respectively). Neither infection with different viral genotypes nor cryoglobulinemia caused an alteration in biomarker levels.
Conclusion
Chronic hepatitis C virus infection alters the levels of some biomarkers, which are mainly observed in patients with liver fibrosis and hepatic necroinflammatory activity.
Similar content being viewed by others
References
Tellinghuisen T, Rice C. Interaction between hepatitis C virus proteins and host cell factors. Curr Opin Microbiol. 2002;5:419–27.
Chen S, Morgan T. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci. 2006;3:47–52.
Dustin L, Rice C. Flying under the radar: the immunobiology of hepatitis C. Ann Rev Immunol. 2007;25:71–99.
Atta AM, Estevam P, Paraná R, Pereira CM, Leite BC, Sousa-Atta ML. Antiphospholipid antibodies in Brazilian hepatitis C virus carriers. Braz J Med Biol Res. 2008;41:489–92.
Atta AM, Oliveira IS, Sousa GM, Paraná R, Sousa Atta ML. Serum cytokine profile in hepatitis C virus carriers presenting cryoglobulinaemia and non-organ-specific autoantibodies. Microb Pathogen. 2010;48:53–6.
Gramenzi A, Andreone P, Loggi E, Foschi F, Cursaro C, Margotti M, et al. Cytokine profile of peripheral blood mononuclear cells from patients with different outcomes of hepatitis C virus infection. J Viral Hepat. 2005;12:525–30.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–54.
Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group. Hepatology. 1996;24:289–93.
Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat. 2002;9:128–33.
Rosenthal-Allieri M, Peritore M-L, Tran A, Halfon P, Benzaken S, Bernard A. Analytical variability of the Fibrotest proteins. Clin Biochem. 2005;38:473–8.
Bacq Y, Schillio Y, Brechot J, De Muret A, Dubois F, Metman E. Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol Clin Biol. 1993;17:364–9.
Kasvosve I, Gomo Z, Gangaidzo I, Mvundura E, Saungweme T, Moyo V, et al. Reference range of serum haptoglobin is phenotype-dependent in blacks. Clin Chim Acta. 2000;296:163–70.
Hochepied T, Berger FG, Baumann H, Libert C. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 2003;14:25–34.
Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta. 2000;1482:157–71.
Anderson N, Pollacchi A, Hayes P, Therapondos G, Newsome P, Boyter A, Smith K. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases. Biomed Chromatogr. 2002;16:365–72.
Propst T, Propst A, Dietze O, Judmaier G, Braunsteiner H, Vogel W. High prevalence of viral infection in adults with homozygous and heterozygous alpha 1-antitrypsin and chronic liver disease. Ann Intern Med. 1992;117:641–5.
Elzouki AN, Verbaan H, Lindgren S, Widell A, Carlson J, Eriksson S. Serine protease inhibitors in patients with chronic viral hepatitis. J Hepatol. 1997;27:42–8.
Lin T, Liao L, Lin S, Lin C, Chang T. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol. 2006;12:4897–901.
Fabris C, Toniutto P, Scott C, Falleti E, Avellini C, Del Forno M, et al. Serum iron indices as a measure of iron deposits in chronic hepatitis C. Clin Chim Acta. 2001;304:49–55.
Metwally M, Zein C, Zein N. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol. 2004;99:286–91.
Guyader D, Thirouard A, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol. 2007;46:587–95.
Shan Y, Lambrecht RW, Bonkovsky HL. Association of hepatitis C virus infection with serum iron status: analysis of data from the third national health and nutrition examination survey. Clin Infect Dis. 2005;40:834–41.
Sousa GM, Oliveira RC, Pereira MM, Paraná R, Sousa-Atta MLB, Atta AM. Autoimmunity in hepatitis C virus carriers: involvement of ferritin and prolactin. Autoimmun Rev. 2011;10:210–3.
Distante S, Bjoro K, Hellum K, Myrvang B, Berg J, Skaug K, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver. 2002;22:269–75.
Kalabay L, Nemesánszky E, Csepregi A, Pusztay M, Dávid K, Horváth G, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol. 2004;16:51–4.
Nascimento M, Bruchfeld A, Suliman M, Hayashi S, Pecoits-Filho R, Manfro R, et al. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res. 2005;38:783–8.
Kessel A, Elias G, Pavlotzky E, Zuckerman E, Rosner I, Toubi E. Anti-C-reactive protein antibodies in chronic hepatitis C infection: correlation with severity and autoimmunity. Hum Immunol. 2007;68:844–8.
Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB. Hepatitis C virus proteins inhibit C3 complement production. J Virol. 2012;86:2221–8.
Dumestre-Perard C, Ponard D, Drouet C, Leroy V, Zarski J-P, Dutertre N, Colomb MG. Complement C4 monitoring in the follow-up of chronic hepatitis C treatment. Clin Exp Immunol. 2002;127:131–6.
Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5:227–36.
Acknowledgments
Maria L.B. Sousa Atta, Ajax M. Atta and R. Paraná have fellowships for Research Productivity from the Brazilian National Council for Scientific and Technological Development (CNPq). The research was supported by CNPq (No.486187/2006-3).
Author information
Authors and Affiliations
Corresponding author
Additional information
Responsible Editor: Kumar Visvanathan.
Rights and permissions
About this article
Cite this article
Atta, M., Cabral, M., Santos, G. et al. Inflammation biomarkers in chronic hepatitis C: association with liver histopathology, HCV genotype and cryoglobulinemia. Inflamm. Res. 61, 1101–1106 (2012). https://doi.org/10.1007/s00011-012-0502-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00011-012-0502-2